Peter Rosholm

Part of Sartorius AG, Albumedix Ltd. is a British science-driven company and recognized leader of albumin-enabled solutions. The company, based in Nottingham, UK, was founded in 1984 with a mission to empower excellence. Albumedix has supported its life-science partners in delivering safe doses of clinical and marketed therapeutics. The company's solutions include the world's only USP-NF compliant recombinant human albumin, client-centric development and compliance services, and drug-enhancing technologies. By challenging the status quo and striving for more, Albumedix enables the development and commercialization of advanced therapies and next-generation biopharmaceuticals. Albumedix is the world leader in recombinant human albumin and has developed a portfolio of products known as Recombumin®. Founded in 1973, the CEO of Albumedix is Jonas S. Moller. The company was acquired by Sartorius Stedim Biotech SA on September 30, 2022, for $500.47 million.

Novozymes A/S engages in the research and development of biotechnology solutions, which produces industrial enzymes and microorganisms. Its business areas include agriculture, bioenergy, biopharma, food and beverage, household care, leather, pulp and paper, textile and wastewater solutions. The company was founded in 2000 and is headquartered in Copenhagen, Denmark.